Press Release

Date: 11th August, 2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Subject: Investors Press Release on the Standalone & Consolidated Un-audited financial results for the quarter ended 30.06.2026. Pursuant to Regulation 30(6) of the SEBI (LODR) Regulations 2015, please find the enclosed herewith the Press Release on the Standalone & Consolidated Un-audited financial results for the quarter ended 30.06.2026. The Investor Press Release may also be accessed on the website of the Company at https://www.saiparenterals.com/ Request you to kindly take the same on record. Thanking you, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) Encl: As above Investor Release Sai Parenterals Limited Q1 FY27 Financial & Business Highlights Mumbai, 11th August 2026 – Sai Parenterals Limited, is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals — contract development and manufacturing for Indian and multinational customers, and branded generic formulations sold domestically and exported into regulated and semi-regulated markets. It has announced its un-audited Financial Results for the quarter ended 30th June 2026. Total Revenue Gross Profit EBITDA PAT Rs. 76 crores Rs. 27 crores Rs. 8 crores Rs. 182 crores Margin 41.8% Margin 14.9% Margin 4.3% Consolidated For Q1FY27 Key Consolidated Financial Highlights Particulars (in Rs. Crs.) Q1 FY27 Q1 FY26 Revenue From Operations 178.7 33.4 Total Revenue 182.4 34.6 Gross Profit 76.2 12.7 Gross Profit Margin (%) 41.8% 36.7% EBITDA 27.3 5.9 EBITDA Margin (%) 14.9% 17.1% PAT 7.9 1.4 PAT Margin (%) 4.3% 4.1% Note: Consolidated figures for Q1FY27 include a full quarter of Noumed Pharmaceuticals; Q1FY26 does not, Noumed having been consolidated with effect from November 12, 2025. Year-on-year comparison is accordingly not like-for-like. • Revenue stood at Rs. 182.4 crore. Revenue for the quarter represents approximately 24% of the FY27 revenue target of Rs. 750 crore, ahead of the phasing implied by the guided 45:55 split between the two halves. • Gross profit stood at Rs. 76.2 crore with gross margin at 41.8%, an expansion 370 bps q-o-q against 38.1% in Q4FY26. Recovery of raw material cost increases remains partial, as contractual arrangements provide customers a 90-day window before a revised price takes effect. • EBITDA stood at Rs. 27.3 crore with EBITDA margin at 14.9% during the quarter, an improvement of 50 bps over 14.4% in Q4FY26, despite absorbing elevated air-freight costs in Australia arising from industry-wide shipping disruption. • Profit After Tax stood at Rs. 7.9 crore for Q1FY27, with PAT margin at 4.3%. • Group composition — the standalone entity contributed 31% of consolidated revenue but 61% of consolidated EBITDA, reflecting that the Noumed platform presently operates at a distribution margin pending the commencement of in-house manufacturing at Adelaide and the progressive internalisation of outsourced volumes. Investor Release Key Standalone Financial Highlights Particulars (in Rs. Crs.) Q1 FY27 Q1 FY26 YoY Revenue From Operations 52.8 19.2 174.9% Total Revenue 56.2 20.4 174.8% Gross Profit 22.1 9.8 126.5% Gross Profit Margin (%) 39.3% 47.7% EBITDA 16.8 4.3 292.7% EBITDA Margin (%) 29.8% 20.9% PAT 8.9 0.8 975.1% PAT Margin (%) 15.8% 4.0% • Revenue stood at Rs. 56.2 crore, registering a robust 174.8% y-o-y growth as against Q1FY26 revenue of Rs. 20.4 crore. • Gross profit stood at Rs. 22.1 crore with gross margin at 39.3%. • EBITDA stood at Rs. 16.8 crore, up 292.7% y-o-y, compared to Rs. 4.3 crore in Q1FY26. EBITDA margin stood at 29.8% during the quarter, an expansion of 890 bps y-o-y, on account of operating leverage. • Profit After Tax stood at Rs. 8.9 crore for Q1FY27, registering a 975.1% y-o-y growth, compared to Rs. 0.8 crore in Q1FY26. PAT margin stood at 15.8%. Key Business and Strategic Developments Proposed variation in the utilisation of IPO proceeds • The Board of Directors has approved a proposed variation in the objects of the issue, redeploying Rs. 83.83 crore earmarked for the capacity expansion and upgradation of manufacturing facilities and Rs. 18.02 crore earmarked for a new research and development centre towards majority stakes in two operating pharmaceutical assets. • The purpose for which the IPO funds were raised — EU-GMP compliant injectable capacity for regulated markets and a dedicated research and development platform — remains unchanged; only the manner of execution is being varied. The proposal is subject to the approval of shareholders. New critical-care injectable facility — acquisition of a 60% stake in Saicriti Pharma Private Limited • The Company proposes to acquire a 60% equity stake in Saicriti Pharma Private Limited, a newly established company, for Rs. 83.83 crore. Saicriti has been formed to construct a critical-care injectable facility at Gummadidala, outside the Outer Ring Road, on a site of over 15,000 square yards, where approvals are in place and civil work is already under way. This is an investment into a project under construction, not the purchase of an established business. • The facility is being built to EU-GMP and USFDA standards, with dedicated capability in complex injectables, lyophilisation and GLP-compliant laboratories, alongside general injectable capacity. Investor Release Key Business and Strategic Developments • Total project cost is estimated at Rs. 215 crore. The Company’s contribution of Rs. 83.83 crore is unchanged from the amount originally earmarked for upgrading Units I and II; the balance 40% equity of Rs. 55.89 crore is funded by the promoters of Saicriti, and the residual requirement through project debt of Rs. 75.24 crore carrying a three- year moratorium and a seven-year repayment schedule. No premium is being paid. The entire Rs. 83.83 crore is applied towards the construction of the facility; no part of it represents consideration for an existing business, a customer base or a management team. • Units I and II at Jeedimetla fall within the Outer Ring Road, where upgradations are no longer permitted under the Hyderabad Industrial Lands Transformation Policy. The site, at approximately 3,100 square yards against the 12,000 to 13,000 square yards an EU-GMP injectable plant of this scale requires, cannot be expanded, and no adjoining land is available. • Building from the ground up would have cost us extended time. A greenfield project begun afresh would have required seven to eight months for land allotment alone before construction could commence, ahead of the build and qualification cycle that follows. • The proposed route delivers approximately 154.66 million units of injectable capacity against approximately 105 million units under the original upgradation plan — roughly 47% more capacity, on a larger and longer-lived asset, at an unchanged outlay from the Company and with completion extended by about one month, to April 2027. Acquisition of a 60% stake in Prathyak Laboratories Private Limited — deepening the research platform • SP Analytics Private Limited, the Company’s dedicated research and development subsidiary, proposes to acquire a 60% equity stake in Prathyak Laboratories Private Limited for Rs. 18.02 crore — the same quantum originally earmarked for a greenfield research centre. • Prathyak operates an established research and development centre at Genome Valley, Hyderabad, with three years of operating history, 65 personnel including 28 research scientists, and a pipeline of 150 SKUs across 86 molecules, with proven capability in lyophilised, liposomal and nano-based complex injectables and in oncology. • Acquiring an operating platform in place of building one allows development work to commence immediately upon acquisit [Showing first 8,000 characters — download PDF for full document]